SynthesisJournal of Alzheimer's disease : JAD2026
Choroid plexus volume in Alzheimer's disease: A systematic review and meta-analysis.
Synthesis in Journal of Alzheimer's disease : JAD, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
BackgroundAlzheimer's disease (AD) is marked by amyloid-β and tau accumulation, processes increasingly linked to impaired protein clearance and neuroinflammation. The choroid plexus (CP), which regulates cerebrospinal fluid (CSF) production and immune signaling, may contribute to these mechanisms. This review aimed to evaluate alterations in CP volume (CPV) in AD and their clinical significance.MethodsPubMed, Embase, Scopus, and Web of Science were searched up to March 2025. Eligible MRI-based studies comparing CPV between AD patients and healthy controls (HCs), as well as investigations examining associations of CPV with demographic, cognitive, structural, and pathological variables, were included. Random-effects models estimated pooled effect sizes, while narrative synthesis explored associations with clinical and pathological features.ResultsSixteen studies (2004 AD; 883 HCs) met inclusion criteria. Pooled findings demonstrated significantly larger CPV in AD relative to HCs (SMD = 1.05, 95% CI: 0.67 to 1.43; p < 0.01). Narrative review indicated consistent links between CP enlargement and worse cognition, hippocampal and cortical atrophy, ventricular expansion, and increased amyloid and tau deposition. CP changes were also associated with impaired glymphatic clearance and systemic inflammation. Notably, enlargement was observed in mild cognitive impairment, suggesting early involvement in the disease course.ConclusionsCP enlargement may represent a neuroimaging feature of AD, reflecting the interplay between impaired clearance mechanisms and neuroinflammatory processes. Given its visibility on routine MRI, CPV may hold considerable potential as an imaging marker for disease stratification and longitudinal monitoring of AD.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.